Literature DB >> 1701507

[Epidemic keratoconjunctivitis: treatment results during an epidemic].

H Hutter1.   

Abstract

150 patients with adenovirus type 8 infection where treated at random, in a prospective study. Based upon a quantifiable conjunctivitis severity score we tried to find out where there are differences in treatment. The best results were seen using polyvinylpyrrolidone-iodine (Betaisodona) although it could not prevent totally subepithelial corneal infiltrates. The combination of exogenous interferon alpha with polyvinylpyrrolidone-iodo-drops or trifluorothymidine-drops was less successful. We could not show any prophylactic effect of interferon on uninflamed fellow eyes. Treatment with vasoconstrictor did not show any therapeutic or prophylactic potency. This group of patients must be seen as a control group and the results of effective therapy should significantly differ from the results in this group. Topical corticosteroids should be reserved for severe symptomatic cases and those with iritis and pseudomembranous conjunctivitis. Giving topical corticosteroids in combination with antibiotics we did not find any influence on the incidence of subepithelial keratitis or the number of corneal infiltrates. The mean duration of acute keratoconjunctivitis using this therapy was longer than the mean duration in the control group with vasoconstrictor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1701507     DOI: 10.1055/s-2008-1046272

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  6 in total

Review 1.  Epidemic keratoconjunctivitis: the current situation and recommendations for prevention and treatment.

Authors:  Birthe Meyer-Rüsenberg; Ulrike Loderstädt; Gisbert Richard; Paul-Michael Kaulfers; Caroline Gesser
Journal:  Dtsch Arztebl Int       Date:  2011-07-08       Impact factor: 5.594

2.  Safety and tolerability of a one-time, in-office administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis: The Reducing Adenoviral Patient Infected Days (RAPID) study.

Authors:  Ellen Shorter; Meredith Whiteside; Jennifer Harthan; Mathew S Margolis; Andrew T Hartwick; Spencer Johnson; Mary Migneco; Christina Morettin; Christian K Olson; Julia Huecker; Tammy Than; Mae O Gordon
Journal:  Ocul Surf       Date:  2019-08-08       Impact factor: 5.033

Review 3.  Treatment of viral conjunctivitis with antiviral drugs.

Authors:  Chrysanthi L Skevaki; Ioanna E Galani; Michail V Pararas; Konstantina P Giannopoulou; Athanassios Tsakris
Journal:  Drugs       Date:  2011-02-12       Impact factor: 9.546

4.  Efficacy of topical immunoglobulins against experimental adenoviral ocular infection.

Authors:  Edward C Nwanegbo; Eric G Romanowski; Y Jerold Gordon; Andrea Gambotto
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-09       Impact factor: 4.799

5.  An evidence-based medicine audit of the ophthalmic emergency services unit of King Abdulaziz University Hospital (KAUH).

Authors:  Adel Alsuhaibani; Mohammed AlRajeh; Priscilla Gikandi; Ahmed Mousa
Journal:  Int Ophthalmol       Date:  2017-10-10       Impact factor: 2.031

6.  Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis.

Authors:  Seydi Okumus; Erol Coskun; Mehmet Gurkan Tatar; Erdal Kaydu; Ramazan Yayuspayi; Aysegul Comez; Ibrahim Erbagci; Bulent Gurler
Journal:  BMC Ophthalmol       Date:  2012-08-18       Impact factor: 2.209

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.